STOCK TITAN

Madison Avenue entities disclose 3,606,203 LKFT shares (NYSE: LKFT)

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Madison Avenue-affiliated investors report beneficial ownership of 3,606,203 Ordinary Shares of Lakefront Biotherapeutics. The Schedule 13G states the group (Madison Avenue International LP, Madison Avenue Partners LP, EMAI Management, Madison Avenue GP, Caraway Jackson Investments LLC and Eli Samaha) may be deemed to beneficially own 3,606,203 shares as of June 23, 2026, representing approximately 5.5% of the class based on 65,897,071 Ordinary Shares outstanding as of December 31, 2025. The filing lists shared voting and dispositive power of 3,606,203 shares across the reporting persons and includes a Joint Filing Agreement. The reporting persons disclaim beneficial ownership except to the extent of pecuniary interest.

Positive

  • None.

Negative

  • None.

Insights

Group discloses passive beneficial ownership of 5.5% in LKFT as of June 23, 2026.

The filing identifies a coordinated group of investment entities and an individual—Madison Avenue International LP, related management and ownership entities, and Eli Samaha—reporting shared voting and dispositive power over 3,606,203 shares. The percentage is calculated using the issuer's disclosed total of 65,897,071 Ordinary Shares as of December 31, 2025.

Because this is a Schedule 13G disclosure, it presents as a passive/beneficial ownership report rather than an active transaction. Subsequent filings may update holdings or classification; track later Section 13D/13G amendments for any change in intent or control.

Shares beneficially owned 3,606,203 shares as of <date>June 23, 2026</date>
Percent of class 5.5% based on 65,897,071 shares outstanding as of <date>December 31, 2025</date>
Outstanding shares used for calculation 65,897,071 shares Ordinary Shares outstanding as of <date>December 31, 2025</date>
CUSIP 36315X101 Lakefront Biotherapeutics Ordinary Shares
beneficially owned regulatory
"As of June 23, 2026, Madison Avenue International LP beneficially owned 3,606,203 shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive power regulatory
"Shared Dispositive Power 3,606,203.00"
Schedule 13G regulatory
"Item 1. | (a) | Name of issuer: Lakefront Biotherapeutics"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Joint Filing Agreement legal
"Exhibit A - Joint Filing Agreement"
pecuniary interest financial
"The Reporting Persons disclaim beneficial ownership ... except to the extent of their pecuniary interest therein"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stake does Madison Avenue report in Lakefront Biotherapeutics (LKFT)?

The reporting group indicates beneficial ownership of 3,606,203 Ordinary Shares, equal to approximately 5.5% of the class based on 65,897,071 shares outstanding as of December 31, 2025.

Who are the reporting persons in this Schedule 13G for LKFT?

The filing lists Madison Avenue International LP, Madison Avenue Partners LP, EMAI Management, Madison Avenue GP, Caraway Jackson Investments LLC, and Eli Samaha as the reporting persons, with a common principal address in New York, NY.

What type of ownership/control is reported by Madison Avenue in LKFT?

The cover information shows shared voting and shared dispositive power over 3,606,203 shares, indicating collective control rather than sole voting or sole dispositive authority.

What date and reference outstanding share count does the filing use for the percentage?

The filing states the percentage is based on 65,897,071 Ordinary Shares outstanding as of December 31, 2025, and reports the reporting persons' holdings as of June 23, 2026.

Does the filing claim full beneficial ownership of the reported shares?

No; the reporting persons include a disclaimer that they disclaim beneficial ownership except to the extent of their pecuniary interest in the Ordinary Shares reported in the Schedule 13G.





36315X101

(CUSIP Number)
06/15/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Madison Avenue International LP
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Manager of Madison Avenue GP, LLC, its General Partner
Date:06/23/2026
Madison Avenue Partners, LP
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Managing Member of EMAI Management, LLC, its General Partner
Date:06/23/2026
EMAI Management, LLC
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Managing Member
Date:06/23/2026
Madison Avenue GP, LLC
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Manager
Date:06/23/2026
Caraway Jackson Investments LLC
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Member
Date:06/23/2026
Eli Samaha
Signature:/s/ Eli Samaha
Name/Title:ELI SAMAHA
Date:06/23/2026

Comments accompanying signature: *The Reporting Persons disclaim beneficial ownership in the Ordinary Shares reported herein except to the extent of their pecuniary interest therein. The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent. Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).
Exhibit Information

Exhibit A - Joint Filing Agreement